Intraventricular Haemorrhage (Neonatal)

1. Clinical Overview

Definition and Summary

Intraventricular Haemorrhage (IVH), also termed Germinal Matrix Haemorrhage-Intraventricular Haemorrhage (GMH-IVH), represents the most significant neurological complication affecting preterm infants. [1] The haemorrhage originates from the rupture of fragile capillaries within the germinal matrix, a highly vascularised subependymal zone located at the head of the caudate nucleus adjacent to the lateral ventricles. Blood may remain confined to this region or extend into the ventricular system with varying degrees of severity.

The germinal matrix serves as the primary proliferative zone for neuronal and glial precursors destined for the cerebral cortex. This transient structure is most prominent between 23-28 weeks' gestation and gradually involutes by 34-36 weeks, explaining the gestational age-dependent incidence of IVH. [2] The condition ranges from small, clinically silent bleeds detected only on routine ultrasound to catastrophic haemorrhages causing rapid neurological deterioration, cardiovascular collapse, and death.

Key Clinical Facts

Clinical Importance

IVH represents the primary driver of adverse neurodevelopmental outcomes in surviving preterm infants. [3] Severe IVH (Grades III-IV) is associated with cerebral palsy rates of 30-80%, cognitive impairment in 50-60%, and lifelong shunt dependency for hydrocephalus in 30-50% of survivors. [4] Every clinical intervention in the neonatal intensive care unit must be evaluated against its potential to precipitate haemorrhage. Prevention of IVH through careful haemodynamic management during the first 72 hours of life represents the cornerstone of neuroprotection in preterm neonates.

Clinical Pearls

Clinical Pearl: The "Silent Catastrophe": A massive IVH can present with nothing more than an unexplained drop in haematocrit or metabolic acidosis. The fontanelle may remain soft initially if the skull sutures are compliant. ALWAYS perform cranial ultrasound in any preterm infant who deteriorates without obvious explanation.

Clinical Pearl: Grade IV is Venous Infarction, Not Extension: The pathophysiology of Grade IV (Periventricular Haemorrhagic Infarction - PVHI) is not simply blood "pushing" into the brain parenchyma. The large intraventricular clot obstructs the terminal vein, causing venous congestion, stasis, and haemorrhagic infarction of the periventricular white matter. This distinction is critical because damage is typically asymmetric and the location determines the specific motor deficit pattern. [5]

Clinical Pearl: The 72-Hour Danger Zone: The germinal matrix vasculature is maximally fragile during the first 72 hours of life. Any rapid haemodynamic perturbation (bolus fluid, pneumothorax, fighting the ventilator, suctioning) can rupture these vessels. "Minimal handling" during this period is genuine neuroprotection, not simply gentle nursing care.

---

2. Epidemiology

Incidence by Gestational Age

The incidence of IVH demonstrates a strong inverse relationship with gestational age, reflecting the progressive maturation of the germinal matrix vasculature. [6]

Temporal Trends

The incidence of IVH has decreased substantially over the past four decades due to improvements in perinatal care. [7] The widespread adoption of antenatal corticosteroids, surfactant therapy, less aggressive mechanical ventilation, and improved delivery room stabilisation have contributed to this reduction. However, the absolute number of affected infants remains significant due to improved survival of extremely preterm infants at the limits of viability.

Risk Factor Analysis

Exam Detail: Evidence-Based Risk Factors for IVH

The aetiology of IVH is multifactorial, involving the interaction of intrinsic vascular fragility with extrinsic haemodynamic and inflammatory stressors. Understanding these risk factors is essential for prevention.

Maternal/Antenatal Factors:

Neonatal Factors (Haemodynamic Instability):

High-Risk Populations

The following populations warrant heightened surveillance and preventive interventions:

1. Extreme Preterms (less than 28 weeks): Mandatory screening protocol with serial cranial ultrasound
2. Extremely Low Birth Weight (less than 1000g): Highest absolute risk regardless of gestation
3. Outborn Infants: 2-3 times higher risk than inborn counterparts [8]
4. Infants with RDS requiring mechanical ventilation: Especially those with pneumothorax or fighting the ventilator
5. Infants born without antenatal steroid exposure: Emergency delivery, concealed labour
6. Infants with early-onset sepsis or confirmed chorioamnionitis: Fetal inflammatory response syndrome

---

3. Pathophysiology

The Germinal Matrix: Anatomical Vulnerability

The germinal matrix (GM) is a highly cellular, richly vascularised transient structure located in the subependymal region of the developing brain, most prominent at the thalamostriate groove near the head of the caudate nucleus. [9]

Developmental Timeline:

• Peak development: 23-28 weeks' gestation (maximum vascularity)
• Involution begins: 28-30 weeks
• Complete involution: 34-36 weeks
• Absent at term: Explains rarity of IVH in term neonates

Structural Vulnerability:

The germinal matrix vasculature is uniquely susceptible to haemorrhage due to several intrinsic and extrinsic factors:

Exam Detail: Intrinsic Vascular Factors:

Extrinsic Factors:

The Pressure-Passive Circulation

In healthy adults and term neonates, cerebral blood flow (CBF) is maintained constant over a wide range of systemic blood pressures through autoregulation. In sick preterm infants, this protective mechanism is frequently impaired or absent. [10]

Normal Autoregulation:

• CBF remains constant between MAP 50-150 mmHg (adults)
• Cerebral vessels dilate when BP falls; constrict when BP rises
• Protects brain from both ischaemia (low pressure) and haemorrhage (high pressure)

Pressure-Passive State (Sick Preterms):

• Autoregulation lost due to immaturity, hypoxia, infection, acidosis
• CBF passively follows systemic BP
• BP rises rapidly → CBF surges → Vessel rupture → IVH
• BP falls → CBF drops → Ischaemia → PVL

This explains why both hypertension AND hypotension are dangerous, and why blood pressure stability is more important than absolute blood pressure values.

Venous Infarction: The Pathogenesis of Grade IV (PVHI)

Grade IV IVH, now more accurately termed Periventricular Haemorrhagic Infarction (PVHI), represents a distinct pathological entity rather than simple extension of intraventricular blood into the brain parenchyma. [11]

Mechanism:

1. Large intraventricular haemorrhage fills the ventricle
2. Terminal vein compression/obstruction by clot at the caudothalamic notch
3. Medullary vein congestion - these veins drain the periventricular white matter into the terminal vein
4. Venous stasis and increased venous pressure in the white matter
5. Haemorrhagic venous infarction - tissue becomes congested, ischaemic, then haemorrhagic
6. Porencephalic cyst formation - infarcted tissue eventually liquefies, leaving a cystic cavity

Clinical Implications:

• PVHI is typically unilateral (or asymmetric) because it depends on which terminal vein is obstructed
• Location determines clinical outcome: frontal involvement affects cognition; parietal involvement causes motor deficits (hemiplegia)
• The prognosis is worse than Grade III because of direct parenchymal destruction

Molecular Pathophysiology

Exam Detail: Cellular and Molecular Mechanisms:

The pathogenesis of GMH-IVH involves complex interactions at the molecular level:

1. Vascular Endothelial Factors:

• VEGF overexpression: Germinal matrix has highest VEGF expression in developing brain, promoting rapid angiogenesis but creating immature vessels [12]
• Angiopoietin-2 imbalance: Ang-2 promotes vascular remodelling but destabilises vessels when Ang-1 (stabilising) is deficient
• Tight junction immaturity: Reduced claudin-5 and occludin expression in GM capillaries

2. Extracellular Matrix Deficiency:

• Reduced collagen IV, fibronectin, laminin
• Low transforming growth factor-beta (TGF-beta) signalling
• Insufficient pericyte coverage

3. Inflammatory Cascade:

• Chorioamnionitis triggers fetal inflammatory response
• IL-1beta, IL-6, TNF-alpha damage blood-brain barrier
• Microglial activation amplifies injury
• Complement activation (C3a, C5a) promotes thrombosis and inflammation

4. Haem Toxicity (Secondary Injury):

• Free haemoglobin releases iron (Fenton reaction)
• Iron catalyses reactive oxygen species (ROS) formation
• ROS damage to oligodendrocyte precursors
• Contributes to white matter injury and PHH development

5. Post-Haemorrhagic Hydrocephalus (PHH) Pathophysiology:

• Blood breakdown products cause chemical arachnoiditis
• Fibrosis of arachnoid granulations impairs CSF absorption
• Ependymal damage disrupts CSF flow
• Iron-induced inflammation perpetuates damage

Neuroanatomy for the Neonatologist

Ventricular System:

Venous Drainage:

---

4. Classification

Papile Classification (1978)

The Papile classification remains the most widely used grading system globally since its introduction in 1978. [13] It provides a standardised framework for describing IVH severity, guiding management decisions, and predicting neurodevelopmental outcomes.

Alternative Classification Systems

Volpe Classification:

The Volpe classification differs primarily in its interpretation of Grade IV:

Volpe argues that the term "Grade IV" implies a continuum of haemorrhage severity, whereas PVHI is pathophysiologically distinct (venous infarction, not haemorrhage extension). This terminology is increasingly preferred in research literature.

Laterality and Location

Documentation Requirements:

When reporting IVH, specify:

1. Grade (I-IV) for each side independently
2. Laterality (unilateral vs bilateral)
3. Location of PVHI if present (frontal, parietal, temporal)
4. Associated findings (cysts, ventriculomegaly, cerebellar haemorrhage)

Example Documentation:

• "Grade II IVH bilaterally"
• "Right Grade III IVH, Left Grade II IVH, bilateral ventriculomegaly"
• "Left Grade IV (PVHI, fronto-parietal), Right Grade II IVH"

Prognostic Implications by Grade

Exam Detail: Neurodevelopmental Outcomes by IVH Grade:

Data derived from EPIPAGE-2, ELGAN, and other large cohort studies. [14,15]

---

5. Clinical Presentation

Presentations of Acute Haemorrhage

IVH presentation varies widely from clinically silent bleeds detected incidentally on routine screening to catastrophic deterioration:

1. Catastrophic Deterioration (Rare, less than 5%):

• Sudden onset of flaccidity, unresponsiveness
• Apnoea requiring emergency intubation
• Bradycardia progressing to cardiovascular collapse
• Fixed, dilated pupils
• Bulging fontanelle
• Rapidly falling haematocrit
• Typically associated with massive Grade III-IV haemorrhage

2. Saltatory Deterioration (10-20%):

• Stuttering deterioration over hours
• Progressive hypotonia and decreased spontaneous movement
• Subtle seizures (eye deviation, cycling movements)
• Increasing oxygen requirement
• Metabolic acidosis
• Hypotension requiring inotropes

3. Silent Presentation (75-85%):

• No clinical signs
• Detected only on routine cranial ultrasound screening
• Most common presentation for Grade I-II IVH
• Emphasises importance of systematic screening protocol

Signs of Acute Haemorrhage

Signs of Post-Haemorrhagic Ventricular Dilation (PHVD)

PHVD typically develops 1-4 weeks after the initial haemorrhage:

Neurological Examination

Systematic Assessment of Neuro-Compromised Neonate:

---

6. Investigations

Cranial Ultrasound (CUS): The Gold Standard

Cranial ultrasound remains the primary diagnostic modality for IVH due to its portability, lack of ionising radiation, repeatability, and excellent sensitivity for detecting germinal matrix and intraventricular haemorrhage. [16]

Standard CUS Screening Protocol for Preterm Infants (less than 32 weeks):

Standard Views:

CUS Findings by IVH Grade:

Ventricular Measurements for PHVD:

MRI Brain

MRI is not used for acute diagnosis but provides superior assessment of white matter injury, myelination, and cerebellar pathology. [17]

Indications:

• Term equivalent age (38-42 weeks PMA) for all infants with Grade II-IV IVH
• Unexplained neurological abnormality not explained by CUS
• Pre-surgical planning for shunt placement
• Prognostic counselling for families

MRI Findings:

Near-Infrared Spectroscopy (NIRS)

NIRS provides continuous, non-invasive monitoring of regional cerebral oxygen saturation (rScO2). [18]

Role in IVH:

• Identifies loss of autoregulation (CBF varies with BP)
• Detects low cerebral oxygenation states before clinical deterioration
• May predict IVH development (fluctuating rScO2)
• Guides haemodynamic management

Target Ranges:

• rScO2: 55-85% (preterm infants)
• FTOE (Fractional Tissue Oxygen Extraction): less than 40%
• Significant deviation correlates with adverse outcomes

Amplitude-Integrated EEG (aEEG)

Continuous brain function monitoring using simplified EEG:

Utility:

• Detection of subclinical seizures (common in IVH)
• Background pattern assessment (burst suppression = poor prognosis)
• Monitoring sedation depth
• Prognostic information (continuous normal voltage pattern favourable)

Laboratory Investigations

---

7. Prevention

The Neuroprotection Bundle

Prevention of IVH requires a systematic, bundle-based approach addressing all modifiable risk factors. [19] The following interventions have evidence supporting their role in IVH prevention:

Antenatal Prevention

1. Antenatal Corticosteroids (Level I Evidence):

Antenatal corticosteroids are the single most effective intervention for preventing IVH. [20]

2. Magnesium Sulphate for Neuroprotection:

3. In Utero Transfer:

All women at risk of preterm delivery less than 32 weeks should be transferred to a tertiary centre with Level III NICU BEFORE delivery. Outborn infants have 2-3 times higher IVH risk.

Delivery Room and Golden Hour Interventions

Delayed Cord Clamping (DCC) - Level I Evidence:

Delivery Room Temperature Management:

Gentle Ventilation:

NICU Prevention Bundle (First 72 Hours)

Exam Detail: The Neuroprotection Bundle: Evidence-Based Interventions

Nursing Care for Neuroprotection:

Pharmacological Prevention

Prophylactic Indomethacin:

---

8. Management

Acute Management of IVH

Once IVH has occurred, management is primarily supportive with focus on preventing extension and secondary injury:

Immediate Stabilisation:

Preventing Haemorrhage Extension:

Seizure Management

Seizures occur in 10-20% of infants with moderate-severe IVH:

Anaemia Management

Management of Post-Haemorrhagic Hydrocephalus (PHH)

PHH develops in 25-50% of infants with Grade III-IV IVH and requires systematic surveillance and staged intervention. [22]

Monitoring Protocol:

ELVIS Trial Intervention Thresholds:

The ELVIS trial established that early intervention (when VI crosses 97th centile + 4mm) leads to better neurodevelopmental outcomes and fewer permanent shunts than late intervention (waiting for symptoms or rapid head growth). [23]

Therapeutic Escalation for PHH

Exam Detail: Staged Approach to PHH Management:

Stage 1: Observation (Mild PHVD)

• VI slightly elevated but less than 97th centile + 4mm
• Weekly ultrasound monitoring
• Many cases stabilise or resolve spontaneously
• No intervention unless progressing

Stage 2: Lumbar Puncture (Historical; Now Rarely Used)

• Previously used for temporary CSF removal
• High infection risk; inconsistent pressure relief
• Ineffective for long-term management
• Only considered if communicating hydrocephalus confirmed

Stage 3: Ventricular Access Device (VAD) - Standard of Care

VAD/Reservoir Insertion:

• Performed by paediatric neurosurgeon
• General anaesthesia required
• Ventricular catheter placed into lateral ventricle
• Reservoir positioned subcutaneously over skull

Reservoir Tapping Protocol:

Stage 4: DRIFT (Drainage, Irrigation, Fibrinolytic Therapy)

Pioneered by Whitelaw et al, DRIFT aims to remove blood breakdown products before they cause permanent arachnoid fibrosis. [24]

Stage 5: Endoscopic Third Ventriculostomy (ETV)

Stage 6: Ventriculoperitoneal (VP) Shunt - Definitive

Communication with Families

Breaking Bad News Framework (Grade III-IV IVH):

Phase 1: Preparation and Setting

• Private, quiet room
• Both parents present if possible
• Sufficient time (no interruptions)
• Diagram of brain available

Phase 2: Information Giving

• "I'm afraid the scan today showed some bleeding in [name's] brain."
• Use diagrams: "This bright area is blood in the fluid spaces."
• Be clear about severity: "This is a significant finding that we need to discuss."
• Avoid jargon: "Grade 4" means little to families

Phase 3: Acknowledging Uncertainty

• "What does this mean for the future?"
• Honest answer: "We cannot know for certain yet."
• "The brain is remarkable at adapting, especially in babies. Other parts can sometimes take over for damaged areas."
• Avoid false hope ("He'll be fine") or excessive pessimism ("He'll be severely disabled")
• "We will follow his development very closely over the coming months and years."

Phase 4: The Plan

• "We are measuring his head size daily."
• "We will repeat the ultrasound in 3 days."
• "Right now, our focus is keeping his blood pressure steady to prevent more bleeding."
• "We have specialists who will help him develop as well as possible."

---

9. Complications

Acute Complications

Long-Term Complications

Post-Haemorrhagic Hydrocephalus (PHH):

Cerebral Palsy:

Cognitive Impairment:

• Grade I-II: Mild reduction in IQ (5-10 points below peers)
• Grade III: Moderate impairment (25-35% IQ less than 70)
• Grade IV: Severe impairment common (50-70% IQ less than 70)

Visual Impairment:

Epilepsy:

• Grade III-IV: 15-30% develop epilepsy
• Often refractory to first-line medications

---

10. Prognosis and Outcomes

Neurodevelopmental Outcomes by Grade

Exam Detail: Outcomes at 2 Years (Corrected Age):

Outcomes at School Age (6-10 Years):

Data synthesised from EPIPAGE-2, ELGAN, EPICure, and Victorian Infant Collaborative studies. [14,15,25]

Key Prognostic Factors

Predictive Value of MRI at Term Equivalent Age

Long-Term Follow-Up Protocol

---

11. Prevention Guidelines and Evidence

Key Guidelines

Evidence Summary Table

---

12. Viva Preparation

Opening Statement

Viva Point: "Intraventricular haemorrhage is the most common neurological complication of prematurity, originating from rupture of fragile germinal matrix vessels in the subependymal zone. It affects 20-25% of very low birth weight infants, with 90% occurring within the first 72 hours of life. The Papile classification grades severity from I to IV, with Grade IV representing periventricular haemorrhagic venous infarction rather than haemorrhage extension. Prevention through antenatal steroids, delayed cord clamping, and haemodynamic stability is paramount, as severe IVH carries a 30-80% risk of cerebral palsy."

Common Viva Questions with Model Answers

Q1: "What are the risk factors for IVH?"

"Risk factors can be divided into antenatal and neonatal factors:

Antenatal factors include lack of antenatal corticosteroids, which is the strongest modifiable risk factor, chorioamnionitis causing fetal inflammatory response, and outborn delivery without in utero transfer.

Neonatal factors relate to haemodynamic instability in a pressure-passive cerebral circulation: respiratory distress syndrome, pneumothorax, rapid volume boluses, hypotension requiring inotropes, patent ductus arteriosus, hypothermia, coagulopathy, and hypocapnia.

Male sex confers a modest increased risk, while preeclampsia may be protective through accelerated vascular maturation."

Q2: "Describe the pathophysiology of Grade IV IVH."

"Grade IV IVH, more accurately termed periventricular haemorrhagic infarction or PVHI, is not simply blood extending into brain tissue. The pathophysiology is venous:

A large intraventricular haemorrhage obstructs the terminal vein at the caudothalamic notch. This vein drains the periventricular white matter via medullary veins. Obstruction causes venous stasis, congestion, and eventually haemorrhagic infarction of the white matter.

This explains why PVHI is typically unilateral or asymmetric - it depends on which terminal vein is obstructed. The location of the infarct, whether frontal or parietal, determines the pattern of neurological deficit, typically contralateral spastic hemiplegia."

Q3: "How would you prevent IVH in an extremely preterm infant?"

"Prevention requires a bundle approach targeting all modifiable risk factors:

Antenatally: Ensure antenatal corticosteroids are administered, ideally 24-48 hours before delivery. Administer magnesium sulphate for neuroprotection. Arrange in utero transfer to a tertiary centre.

At delivery: Delayed cord clamping for at least 60 seconds. Ensure thermal stability with plastic wrap and warm delivery room. Avoid excessive resuscitation and maintain gentle ventilation.

In the NICU during the first 72 hours: Midline head positioning with 30-degree elevation. Minimal handling with clustered care. Slow administration of IV fluids over 20-30 minutes, never rapid boluses. Avoid hypocarbia and maintain stable PaCO2. Closed suction systems. Adequate analgesia. Some units use prophylactic indomethacin, though evidence for long-term benefit is limited."

Q4: "How do you manage post-haemorrhagic hydrocephalus?"

"Management follows a staged approach based on ventricular measurements and clinical signs:

Monitoring: Serial cranial ultrasound measuring ventricular index. The ELVIS trial established that early intervention when VI exceeds the 97th centile plus 4mm leads to better outcomes than waiting for symptoms.

Temporary CSF drainage: A ventricular access device such as an Ommaya reservoir is inserted by neurosurgery. This is tapped regularly, typically 10-15mL/kg at a maximum rate of 1mL per minute, to control ICP while the infant grows.

DRIFT may be considered in specialist centres - this involves ventricular irrigation with tPA to clear blood products and prevent arachnoid fibrosis, which can reduce long-term disability.

Definitive management is a ventriculoperitoneal shunt, performed when the infant weighs over 2kg and CSF protein is below 1.5g/L to reduce blockage risk. Endoscopic third ventriculostomy is an alternative in obstructive hydrocephalus but has lower success rates in young infants."

Common Examiner Traps

---

13. Clinical FAQ (Parent Information)

Q: Will the blood go away? A: Yes. The body gradually reabsorbs the blood clot over 4-6 weeks. However, the bleeding can sometimes leave behind damage to the drainage pathways, leading to fluid build-up (hydrocephalus), or damage to the brain tissue itself.

Q: Did I cause this? A: No. IVH is a complication of premature birth itself. It is not caused by anything you did or didn't do during pregnancy. The blood vessels in premature babies' brains are simply very fragile.

Q: What is a "reservoir"? A: A reservoir is a small plastic dome placed under the scalp, connected to a tube going into the fluid space in the brain. It allows us to remove excess fluid with a small needle without hurting your baby each time. It buys time for your baby to grow big enough for a permanent drainage system if needed.

Q: Can the brain heal? A: The baby brain has remarkable "plasticity"

• the ability to rewire itself. Other parts of the brain can sometimes take over functions from damaged areas. Early physiotherapy and developmental support help maximise this potential.

Q: What will this mean for my child's future? A: This depends on the severity of the bleed. For mild bleeds (Grade I-II), most babies develop normally. For more severe bleeds, there is a risk of problems with movement, learning, or vision. We will follow your child closely with specialist assessments to identify any difficulties early and provide the right support.

---

14. Future Directions

Emerging Therapies

1. Stem Cell Therapy:

2. Erythropoietin (EPO):

3. Novel Anti-Inflammatory Agents:

• IL-1 receptor antagonists (Anakinra)
• Targeted iron chelation (preventing haem toxicity)
• TLR4 inhibitors

4. Enhanced Monitoring:

• Continuous autoregulation monitoring (correlation of BP and rScO2)
• Real-time CBF measurement
• AI-based prediction models for IVH risk

5. Artificial Womb (Ectogenesis):

---

15. References

1. Volpe JJ. Intraventricular hemorrhage in the premature infant—current concepts. Part I. Ann Neurol. 1989;25(1):3-11. doi:10.1002/ana.410250103

2. Ballabh P. Pathogenesis and prevention of intraventricular hemorrhage. Clin Perinatol. 2014;41(1):47-67. doi:10.1016/j.clp.2013.09.007

3. Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126(3):443-456. doi:10.1542/peds.2009-2959

4. Mukerji A, Shah V, Shah PS. Periventricular/intraventricular hemorrhage and neurodevelopmental outcomes: a meta-analysis. Pediatrics. 2015;136(6):1132-1143. doi:10.1542/peds.2015-0944

5. Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol. 2009;8(1):110-124. doi:10.1016/S1474-4422(08)70294-1

6. Bolisetty S, Dhawan A, Abdel-Latif M, et al. Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants. Pediatrics. 2014;133(1):55-62. doi:10.1542/peds.2013-0372

7. Horbar JD, Edwards EM, Greenberg LT, et al. Variation in performance of neonatal intensive care units in the United States. JAMA Pediatr. 2017;171(3):e164396. doi:10.1001/jamapediatrics.2016.4396

8. Chien LY, Whyte R, Aziz K, et al. Improved outcome of preterm infants when delivered in tertiary care centers. Obstet Gynecol. 2001;98(2):247-252. doi:10.1016/s0029-7844(01)01426-3

9. Ballabh P, Braun A, Bhide P, et al. Germinal matrix vasculature: unique features and immature state. Dev Neurosci. 2004;26:114-123. doi:10.1159/000082134

10. Soul JS, Hammer PE, Tsuji M, et al. Fluctuating pressure-passivity is common in the cerebral circulation of sick premature infants. Pediatr Res. 2007;61(4):467-473. doi:10.1203/pdr.0b013e31803237f6

11. Volpe JJ, Inder TE, Darras BT, et al. Volpe's Neurology of the Newborn. 6th ed. Elsevier; 2018.

12. Ballabh P, Xu H, Bhide PG, et al. Angiogenic inhibition reduces germinal matrix hemorrhage. Nat Med. 2007;13(4):477-485. doi:10.1038/nm1558

13. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529-534. doi:10.1016/s0022-3476(78)80282-0

14. Ancel PY, Goffinet F, EPIPAGE-2 Writing Group. Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011. JAMA Pediatr. 2015;169(3):230-238. doi:10.1001/jamapediatrics.2014.3351

15. O'Shea TM, Allred EN, Kuban KC, et al. Intraventricular hemorrhage and developmental outcomes at 24 months of age in extremely preterm infants. J Child Neurol. 2012;27(1):22-29. doi:10.1177/0883073811424462

16. de Vries LS, Benders MJ, Groenendaal F. Imaging the premature brain: ultrasound or MRI? Neuroradiology. 2013;55(Suppl 2):13-22. doi:10.1007/s00234-013-1233-y

17. Inder TE, Warfield SK, Wang H, et al. Abnormal cerebral structure is present at term in premature infants. Pediatrics. 2005;115(2):286-294. doi:10.1542/peds.2004-0326

18. Verhagen EA, Hummel LA, Bos AF, Kooi EMW. Near-infrared spectroscopy to detect absence of cerebrovascular autoregulation in preterm infants. Clin Neurophysiol. 2014;125(1):47-52. doi:10.1016/j.clinph.2013.07.001

19. Rabe H, Gyte GM, Díaz-Rossello JL, Duley L. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database Syst Rev. 2019;9(9):CD003248. doi:10.1002/14651858.CD003248.pub4

20. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454. doi:10.1002/14651858.CD004454.pub3

21. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344(26):1966-1972. doi:10.1056/NEJM200106283442602

22. Robinson S. Neonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and current treatment concepts. J Neurosurg Pediatr. 2012;9(3):242-258. doi:10.3171/2011.12.PEDS11136

23. de Vries LS, Groenendaal F, Liem KD, et al. Treatment thresholds for intervention in posthaemorrhagic ventricular dilatation: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019;104(1):F70-F75. doi:10.1136/archdischild-2017-314206

24. Luyt K, Jary S, Lea C, et al. Ten-year follow-up of a randomised trial of drainage, irrigation and fibrinolytic therapy (DRIFT) in infants with post-haemorrhagic ventricular dilatation. Health Technol Assess. 2019;23(4):1-116. doi:10.3310/hta23040

25. Cheong JLY, Anderson PJ, Burnett AC, et al. Changing neurodevelopment at 8 years in children born extremely preterm since the 1990s. Pediatrics. 2017;139(6):e20164086. doi:10.1542/peds.2016-4086

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines.